Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 ...

The US FDA has approved a new biosimilar of Roche and Novartis' blockbuster ophthalmology therapy Lucentis – Coherus BioSciences' Cimerli – which its developer claims is the first to be fully ...

It cites an “anticompetitive agreement” in the market for Lucentis active ingredient, the anti-VEGF antibody ranibizumab. Specifically, the ACGM claims that the companies entered into a ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

The global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to surpass USD 4,642.9 million ...

Bs: Bevasiranib sodium; CABERNET: A study of Strontium 90 β Radiation With Lucentis to Treat Age-Related Macular Degeneration; CARBON: Combination of Bevasiranib and Lucentis Therapy in Wet AMD ...

Chronic therapy is essential for PCV patients, even after resolution of pigment epithelial detachment, to prevent recurrence.

Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Regeneron (REGN) to $1,150 from $1,200 and keeps an Outperform ...

AIA Group Ltd raised its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 10.6% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,411 shares of the biotechnology company’s stock ...

EQS-News: Formycon AG / Key word (s): Regulatory Admission/IPO Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange 04.11.2024 / 06:30 CET/CEST The issuer is solely ...